LG Chem has started clinical development to develop next-generation osteoarthritis treatments that have not existed before. Osteoarthritis is a degenerative disease that causes pain and gait disorders due to inflammation in the joints and cartilage wear. LG Chem announced on the 4th that it has been approved for phase 1b/2 clinical trials of LG34053, a new drug candidate for osteoarthritis treatment.

The company will conduct a study at SMC to evaluate indicators such as safety and drug resistance, pharmacokinetics (drug absorption, distribution, metabolism, and elimination) and select optimal doses for patients with mild and moderate knee osteoarthritis (K&L 2-3).

LG34053 is an in